nodes	percent_of_prediction	percent_of_DWPC	metapath
Topotecan—Topoisomerase Inhibitors—Doxorubicin—kidney cancer	0.404	1	CiPCiCtD
Topotecan—lung cancer—kidney cancer	0.256	1	CtDrD
Topotecan—ABCB1—kidney cancer	0.072	1	CbGaD
Topotecan—ABCG2—Pazopanib—kidney cancer	0.0176	0.0964	CbGbCtD
Topotecan—ABCG2—Dactinomycin—kidney cancer	0.0161	0.0882	CbGbCtD
Topotecan—ABCG2—Erlotinib—kidney cancer	0.0125	0.0688	CbGbCtD
Topotecan—ABCB1—Temsirolimus—kidney cancer	0.0121	0.0662	CbGbCtD
Topotecan—ABCG2—Paclitaxel—kidney cancer	0.0115	0.063	CbGbCtD
Topotecan—CYP3A4—Everolimus—kidney cancer	0.0107	0.0587	CbGbCtD
Topotecan—ABCG2—Sorafenib—kidney cancer	0.0102	0.0559	CbGbCtD
Topotecan—ABCG2—Vincristine—kidney cancer	0.00989	0.0543	CbGbCtD
Topotecan—ABCG2—Sunitinib—kidney cancer	0.00826	0.0453	CbGbCtD
Topotecan—CYP3A4—Temsirolimus—kidney cancer	0.00722	0.0397	CbGbCtD
Topotecan—ABCB1—Pazopanib—kidney cancer	0.00633	0.0348	CbGbCtD
Topotecan—ABCG2—Doxorubicin—kidney cancer	0.00618	0.0339	CbGbCtD
Topotecan—ABCB1—Dactinomycin—kidney cancer	0.00579	0.0318	CbGbCtD
Topotecan—ABCB1—Gemcitabine—kidney cancer	0.00458	0.0251	CbGbCtD
Topotecan—ABCB1—Erlotinib—kidney cancer	0.00452	0.0248	CbGbCtD
Topotecan—ABCB1—Paclitaxel—kidney cancer	0.00414	0.0227	CbGbCtD
Topotecan—CYP3A4—Pazopanib—kidney cancer	0.00379	0.0208	CbGbCtD
Topotecan—ABCB1—Sorafenib—kidney cancer	0.00367	0.0202	CbGbCtD
Topotecan—ABCB1—Vinblastine—kidney cancer	0.00363	0.0199	CbGbCtD
Topotecan—ABCB1—Vincristine—kidney cancer	0.00357	0.0196	CbGbCtD
Topotecan—ABCB1—Sunitinib—kidney cancer	0.00298	0.0163	CbGbCtD
Topotecan—CYP3A4—Erlotinib—kidney cancer	0.00271	0.0149	CbGbCtD
Topotecan—CYP3A4—Paclitaxel—kidney cancer	0.00248	0.0136	CbGbCtD
Topotecan—ABCB1—Doxorubicin—kidney cancer	0.00223	0.0122	CbGbCtD
Topotecan—CYP3A4—Sorafenib—kidney cancer	0.0022	0.0121	CbGbCtD
Topotecan—CYP3A4—Vinblastine—kidney cancer	0.00217	0.0119	CbGbCtD
Topotecan—CYP3A4—Vincristine—kidney cancer	0.00214	0.0117	CbGbCtD
Topotecan—CYP3A4—Sunitinib—kidney cancer	0.00178	0.00979	CbGbCtD
Topotecan—CYP3A4—Doxorubicin—kidney cancer	0.00134	0.00733	CbGbCtD
Topotecan—Irinotecan—ACHE—kidney cancer	0.000925	0.55	CrCbGaD
Topotecan—Irinotecan—BCHE—kidney cancer	0.000544	0.323	CrCbGaD
Topotecan—TOP1MT—gonad—kidney cancer	0.000423	0.23	CbGeAlD
Topotecan—TOP1—nephron tubule—kidney cancer	0.000274	0.149	CbGeAlD
Topotecan—CYP3A4—urine—kidney cancer	0.000251	0.137	CbGeAlD
Topotecan—TOP1—cortex of kidney—kidney cancer	0.000234	0.128	CbGeAlD
Topotecan—TOP1—Circadian rythm related genes—KCNMA1—kidney cancer	0.000233	0.0161	CbGpPWpGaD
Topotecan—ABCG2—HIF-2-alpha transcription factor network—EPAS1—kidney cancer	0.000231	0.016	CbGpPWpGaD
Topotecan—ABCG2—HIF-2-alpha transcription factor network—VHL—kidney cancer	0.000231	0.016	CbGpPWpGaD
Topotecan—CYP3A4—Aflatoxin activation and detoxification—ACY1—kidney cancer	0.000224	0.0155	CbGpPWpGaD
Topotecan—TOP1—cardiac atrium—kidney cancer	0.000223	0.121	CbGeAlD
Topotecan—ABCG2—HIF-2-alpha transcription factor network—PGK1—kidney cancer	0.000221	0.0154	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—JUND—kidney cancer	0.000217	0.0151	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—APAF1—kidney cancer	0.000217	0.0151	CbGpPWpGaD
Topotecan—Irinotecan—ABCB1—kidney cancer	0.000213	0.127	CrCbGaD
Topotecan—TOP1—Circadian rythm related genes—JUND—kidney cancer	0.000209	0.0145	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—WT1—kidney cancer	0.000206	0.0143	CbGpPWpGaD
Topotecan—ABCG2—HIF-2-alpha transcription factor network—TCEB2—kidney cancer	0.000202	0.014	CbGpPWpGaD
Topotecan—ABCG2—HIF-2-alpha transcription factor network—TCEB1—kidney cancer	0.000202	0.014	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—ACHE—kidney cancer	0.000179	0.0124	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—ANXA1—kidney cancer	0.000165	0.0114	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—JUNB—kidney cancer	0.000148	0.0103	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—PAK1—kidney cancer	0.000148	0.0103	CbGpPWpGaD
Topotecan—CYP3A4—Fatty Acid Omega Oxidation—ALDH1A1—kidney cancer	0.000141	0.00975	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—EGR1—kidney cancer	0.000138	0.0096	CbGpPWpGaD
Topotecan—TOP1—Circadian rythm related genes—EGR1—kidney cancer	0.000133	0.00922	CbGpPWpGaD
Topotecan—ABCG2—Irinotecan Pathway—APC—kidney cancer	0.000131	0.00906	CbGpPWpGaD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—PGK1—kidney cancer	0.00013	0.00904	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—BRCA2—kidney cancer	0.000121	0.00843	CbGpPWpGaD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—NDRG1—kidney cancer	0.000121	0.0084	CbGpPWpGaD
Topotecan—ABCG2—HIF-2-alpha transcription factor network—FLT1—kidney cancer	0.000121	0.00838	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—CDKN2B—kidney cancer	0.00012	0.00835	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—ABCB1—kidney cancer	0.000118	0.00816	CbGpPWpGaD
Topotecan—ABCB1—Allograft Rejection—HARS—kidney cancer	0.000116	0.00805	CbGpPWpGaD
Topotecan—ABCG2—HIF-2-alpha transcription factor network—SLC2A1—kidney cancer	0.000113	0.00782	CbGpPWpGaD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—CA9—kidney cancer	0.000111	0.00768	CbGpPWpGaD
Topotecan—CYP3A4—Aflatoxin B1 metabolism—GSTM1—kidney cancer	0.000102	0.00707	CbGpPWpGaD
Topotecan—ABCG2—nephron tubule—kidney cancer	9.71e-05	0.0529	CbGeAlD
Topotecan—CYP3A4—Codeine and Morphine Metabolism—ABCB1—kidney cancer	9.44e-05	0.00655	CbGpPWpGaD
Topotecan—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—FLT1—kidney cancer	9.02e-05	0.00625	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—APC—kidney cancer	8.48e-05	0.00588	CbGpPWpGaD
Topotecan—CYP3A4—Irinotecan Pathway—BCHE—kidney cancer	8.01e-05	0.00556	CbGpPWpGaD
Topotecan—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—kidney cancer	7.9e-05	0.00548	CbGpPWpGaD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—PGK1—kidney cancer	7.04e-05	0.00488	CbGpPWpGaD
Topotecan—ABCG2—HIF-2-alpha transcription factor network—KDR—kidney cancer	6.97e-05	0.00483	CbGpPWpGaD
Topotecan—ABCB1—Allograft Rejection—LRRK2—kidney cancer	6.67e-05	0.00463	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—RAF1—kidney cancer	6.66e-05	0.00462	CbGpPWpGaD
Topotecan—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—ABCB1—kidney cancer	6.65e-05	0.00461	CbGpPWpGaD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—SLC2A1—kidney cancer	6.63e-05	0.0046	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—ERBB2—kidney cancer	6.58e-05	0.00457	CbGpPWpGaD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—NDRG1—kidney cancer	6.55e-05	0.00454	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—PTGS2—kidney cancer	6.44e-05	0.00447	CbGpPWpGaD
Topotecan—CYP3A4—renal system—kidney cancer	6.15e-05	0.0335	CbGeAlD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—CDKN1B—kidney cancer	6.1e-05	0.00423	CbGpPWpGaD
Topotecan—CYP3A4—Tryptophan metabolism—ALDH1A1—kidney cancer	6.04e-05	0.00419	CbGpPWpGaD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—CA9—kidney cancer	5.99e-05	0.00415	CbGpPWpGaD
Topotecan—CYP3A4—kidney—kidney cancer	5.94e-05	0.0324	CbGeAlD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—CCND1—kidney cancer	5.82e-05	0.00404	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—JUN—kidney cancer	5.81e-05	0.00403	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—CTNNB1—kidney cancer	5.76e-05	0.004	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—PTEN—kidney cancer	5.61e-05	0.0039	CbGpPWpGaD
Topotecan—TOP1—Circadian rythm related genes—JUN—kidney cancer	5.57e-05	0.00387	CbGpPWpGaD
Topotecan—TOP1—Circadian rythm related genes—PTEN—kidney cancer	5.39e-05	0.00374	CbGpPWpGaD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—ABCB1—kidney cancer	5.24e-05	0.00363	CbGpPWpGaD
Topotecan—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—kidney cancer	5.16e-05	0.00358	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	5.07e-05	0.00352	CbGpPWpGaD
Topotecan—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—kidney cancer	4.99e-05	0.00346	CbGpPWpGaD
Topotecan—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—FLT1—kidney cancer	4.87e-05	0.00338	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	4.8e-05	0.00333	CbGpPWpGaD
Topotecan—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—kidney cancer	4.79e-05	0.00332	CbGpPWpGaD
Topotecan—CYP3A4—Estrogen metabolism—GSTM1—kidney cancer	4.79e-05	0.00332	CbGpPWpGaD
Topotecan—ABCB1—nephron tubule—kidney cancer	4.79e-05	0.0261	CbGeAlD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	4.67e-05	0.00324	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	4.56e-05	0.00317	CbGpPWpGaD
Topotecan—CYP3A4—Estrogen metabolism—CYP1A1—kidney cancer	4.54e-05	0.00315	CbGpPWpGaD
Topotecan—ABCB1—renal system—kidney cancer	4.35e-05	0.0237	CbGeAlD
Topotecan—CYP3A4—Irinotecan Pathway—APC—kidney cancer	4.35e-05	0.00302	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	4.31e-05	0.00299	CbGpPWpGaD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—HIF1A—kidney cancer	4.29e-05	0.00297	CbGpPWpGaD
Topotecan—ABCB1—kidney—kidney cancer	4.21e-05	0.0229	CbGeAlD
Topotecan—CYP3A4—Xenobiotics—CYP1A1—kidney cancer	4.17e-05	0.0029	CbGpPWpGaD
Topotecan—ABCB1—cortex of kidney—kidney cancer	4.1e-05	0.0223	CbGeAlD
Topotecan—CYP3A4—Tamoxifen metabolism—CYP1A1—kidney cancer	4.01e-05	0.00278	CbGpPWpGaD
Topotecan—Feeling abnormal—Dactinomycin—kidney cancer	3.99e-05	0.000583	CcSEcCtD
Topotecan—Haemoglobin—Capecitabine—kidney cancer	3.98e-05	0.000583	CcSEcCtD
Topotecan—Skin disorder—Gemcitabine—kidney cancer	3.98e-05	0.000582	CcSEcCtD
Topotecan—Rhinitis—Capecitabine—kidney cancer	3.97e-05	0.000581	CcSEcCtD
Topotecan—Haemorrhage—Capecitabine—kidney cancer	3.96e-05	0.00058	CcSEcCtD
Topotecan—Hyperhidrosis—Gemcitabine—kidney cancer	3.96e-05	0.000579	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	3.96e-05	0.00275	CbGpPWpGaD
Topotecan—CYP3A4—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	3.96e-05	0.00275	CbGpPWpGaD
Topotecan—Gastrointestinal pain—Dactinomycin—kidney cancer	3.95e-05	0.000578	CcSEcCtD
Topotecan—Hypoaesthesia—Capecitabine—kidney cancer	3.94e-05	0.000577	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Vincristine—kidney cancer	3.94e-05	0.000576	CcSEcCtD
Topotecan—Pharyngitis—Capecitabine—kidney cancer	3.93e-05	0.000575	CcSEcCtD
Topotecan—Hypersensitivity—Sorafenib—kidney cancer	3.91e-05	0.000572	CcSEcCtD
Topotecan—Anorexia—Gemcitabine—kidney cancer	3.91e-05	0.000571	CcSEcCtD
Topotecan—Vomiting—Vinblastine—kidney cancer	3.9e-05	0.000571	CcSEcCtD
Topotecan—ABCB1—gonad—kidney cancer	3.9e-05	0.0213	CbGeAlD
Topotecan—Dizziness—Erlotinib—kidney cancer	3.9e-05	0.000571	CcSEcCtD
Topotecan—Ill-defined disorder—Paclitaxel—kidney cancer	3.9e-05	0.00057	CcSEcCtD
Topotecan—Vomiting—Everolimus—kidney cancer	3.89e-05	0.000569	CcSEcCtD
Topotecan—Anaemia—Paclitaxel—kidney cancer	3.89e-05	0.000568	CcSEcCtD
Topotecan—Paraesthesia—Vincristine—kidney cancer	3.88e-05	0.000567	CcSEcCtD
Topotecan—Dermatitis bullous—Doxorubicin—kidney cancer	3.86e-05	0.000565	CcSEcCtD
Topotecan—Rash—Everolimus—kidney cancer	3.86e-05	0.000564	CcSEcCtD
Topotecan—Dermatitis—Everolimus—kidney cancer	3.85e-05	0.000563	CcSEcCtD
Topotecan—ABCG2—Transmembrane transport of small molecules—RYR1—kidney cancer	3.85e-05	0.00267	CbGpPWpGaD
Topotecan—Headache—Vinblastine—kidney cancer	3.85e-05	0.000562	CcSEcCtD
Topotecan—Angioedema—Paclitaxel—kidney cancer	3.84e-05	0.000562	CcSEcCtD
Topotecan—ABCG2—HIF-2-alpha transcription factor network—VEGFA—kidney cancer	3.84e-05	0.00266	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—ACY1—kidney cancer	3.84e-05	0.00266	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	3.83e-05	0.00266	CbGpPWpGaD
Topotecan—Headache—Everolimus—kidney cancer	3.83e-05	0.00056	CcSEcCtD
Topotecan—Body temperature increased—Dactinomycin—kidney cancer	3.82e-05	0.000559	CcSEcCtD
Topotecan—Abdominal pain—Dactinomycin—kidney cancer	3.82e-05	0.000559	CcSEcCtD
Topotecan—Anaphylactoid reaction—Doxorubicin—kidney cancer	3.82e-05	0.000558	CcSEcCtD
Topotecan—Asthenia—Sorafenib—kidney cancer	3.81e-05	0.000557	CcSEcCtD
Topotecan—ABCB1—Allograft Rejection—IL13—kidney cancer	3.81e-05	0.00264	CbGpPWpGaD
Topotecan—Malaise—Paclitaxel—kidney cancer	3.79e-05	0.000554	CcSEcCtD
Topotecan—Lethargy—Doxorubicin—kidney cancer	3.77e-05	0.000551	CcSEcCtD
Topotecan—Leukopenia—Paclitaxel—kidney cancer	3.76e-05	0.00055	CcSEcCtD
Topotecan—Hypersensitivity—Sunitinib—kidney cancer	3.76e-05	0.00055	CcSEcCtD
Topotecan—Decreased appetite—Vincristine—kidney cancer	3.76e-05	0.000549	CcSEcCtD
Topotecan—Pruritus—Sorafenib—kidney cancer	3.76e-05	0.000549	CcSEcCtD
Topotecan—Vomiting—Erlotinib—kidney cancer	3.75e-05	0.000549	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Gemcitabine—kidney cancer	3.73e-05	0.000546	CcSEcCtD
Topotecan—Gastrointestinal disorder—Vincristine—kidney cancer	3.73e-05	0.000545	CcSEcCtD
Topotecan—Fatigue—Vincristine—kidney cancer	3.73e-05	0.000545	CcSEcCtD
Topotecan—Rash—Erlotinib—kidney cancer	3.72e-05	0.000544	CcSEcCtD
Topotecan—Dermatitis—Erlotinib—kidney cancer	3.72e-05	0.000544	CcSEcCtD
Topotecan—Headache—Erlotinib—kidney cancer	3.7e-05	0.000541	CcSEcCtD
Topotecan—Constipation—Vincristine—kidney cancer	3.7e-05	0.00054	CcSEcCtD
Topotecan—Pain—Vincristine—kidney cancer	3.7e-05	0.00054	CcSEcCtD
Topotecan—Paraesthesia—Gemcitabine—kidney cancer	3.68e-05	0.000538	CcSEcCtD
Topotecan—TOP1—Circadian rythm related genes—TP53—kidney cancer	3.68e-05	0.00255	CbGpPWpGaD
Topotecan—Cough—Paclitaxel—kidney cancer	3.67e-05	0.000536	CcSEcCtD
Topotecan—Asthenia—Sunitinib—kidney cancer	3.67e-05	0.000536	CcSEcCtD
Topotecan—Dyspnoea—Gemcitabine—kidney cancer	3.65e-05	0.000534	CcSEcCtD
Topotecan—Nausea—Vinblastine—kidney cancer	3.65e-05	0.000533	CcSEcCtD
Topotecan—Nausea—Everolimus—kidney cancer	3.63e-05	0.000531	CcSEcCtD
Topotecan—Diarrhoea—Sorafenib—kidney cancer	3.63e-05	0.000531	CcSEcCtD
Topotecan—Pruritus—Sunitinib—kidney cancer	3.61e-05	0.000528	CcSEcCtD
Topotecan—Angiopathy—Capecitabine—kidney cancer	3.6e-05	0.000526	CcSEcCtD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—SLC2A1—kidney cancer	3.59e-05	0.00249	CbGpPWpGaD
Topotecan—Immune system disorder—Capecitabine—kidney cancer	3.58e-05	0.000524	CcSEcCtD
Topotecan—Chest pain—Paclitaxel—kidney cancer	3.58e-05	0.000523	CcSEcCtD
Topotecan—Arthralgia—Paclitaxel—kidney cancer	3.58e-05	0.000523	CcSEcCtD
Topotecan—Myalgia—Paclitaxel—kidney cancer	3.58e-05	0.000523	CcSEcCtD
Topotecan—Mediastinal disorder—Capecitabine—kidney cancer	3.57e-05	0.000522	CcSEcCtD
Topotecan—Decreased appetite—Gemcitabine—kidney cancer	3.56e-05	0.000521	CcSEcCtD
Topotecan—Hypersensitivity—Dactinomycin—kidney cancer	3.56e-05	0.000521	CcSEcCtD
Topotecan—Chills—Capecitabine—kidney cancer	3.56e-05	0.00052	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	3.56e-05	0.00052	CcSEcCtD
Topotecan—Gastrointestinal disorder—Gemcitabine—kidney cancer	3.54e-05	0.000517	CcSEcCtD
Topotecan—Discomfort—Paclitaxel—kidney cancer	3.54e-05	0.000517	CcSEcCtD
Topotecan—Fatigue—Gemcitabine—kidney cancer	3.53e-05	0.000517	CcSEcCtD
Topotecan—Gastrointestinal pain—Vincristine—kidney cancer	3.53e-05	0.000517	CcSEcCtD
Topotecan—Cardiac arrest—Doxorubicin—kidney cancer	3.51e-05	0.000514	CcSEcCtD
Topotecan—Dizziness—Sorafenib—kidney cancer	3.51e-05	0.000513	CcSEcCtD
Topotecan—Pain—Gemcitabine—kidney cancer	3.51e-05	0.000512	CcSEcCtD
Topotecan—Constipation—Gemcitabine—kidney cancer	3.51e-05	0.000512	CcSEcCtD
Topotecan—Nausea—Erlotinib—kidney cancer	3.51e-05	0.000512	CcSEcCtD
Topotecan—Alopecia—Capecitabine—kidney cancer	3.5e-05	0.000512	CcSEcCtD
Topotecan—Diarrhoea—Sunitinib—kidney cancer	3.5e-05	0.000511	CcSEcCtD
Topotecan—Asthenia—Dactinomycin—kidney cancer	3.47e-05	0.000507	CcSEcCtD
Topotecan—Malnutrition—Capecitabine—kidney cancer	3.45e-05	0.000505	CcSEcCtD
Topotecan—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—kidney cancer	3.45e-05	0.00239	CbGpPWpGaD
Topotecan—Anaphylactic shock—Paclitaxel—kidney cancer	3.43e-05	0.000502	CcSEcCtD
Topotecan—Abdominal pain—Vincristine—kidney cancer	3.42e-05	0.000499	CcSEcCtD
Topotecan—Body temperature increased—Vincristine—kidney cancer	3.42e-05	0.000499	CcSEcCtD
Topotecan—Infection—Paclitaxel—kidney cancer	3.41e-05	0.000498	CcSEcCtD
Topotecan—Dizziness—Sunitinib—kidney cancer	3.38e-05	0.000494	CcSEcCtD
Topotecan—Feeling abnormal—Gemcitabine—kidney cancer	3.38e-05	0.000494	CcSEcCtD
Topotecan—Vomiting—Sorafenib—kidney cancer	3.38e-05	0.000494	CcSEcCtD
Topotecan—Nervous system disorder—Paclitaxel—kidney cancer	3.37e-05	0.000492	CcSEcCtD
Topotecan—Thrombocytopenia—Paclitaxel—kidney cancer	3.36e-05	0.000491	CcSEcCtD
Topotecan—Rash—Sorafenib—kidney cancer	3.35e-05	0.000489	CcSEcCtD
Topotecan—Dermatitis—Sorafenib—kidney cancer	3.34e-05	0.000489	CcSEcCtD
Topotecan—Back pain—Capecitabine—kidney cancer	3.34e-05	0.000488	CcSEcCtD
Topotecan—Skin disorder—Paclitaxel—kidney cancer	3.33e-05	0.000487	CcSEcCtD
Topotecan—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	3.33e-05	0.000486	CcSEcCtD
Topotecan—Headache—Sorafenib—kidney cancer	3.33e-05	0.000486	CcSEcCtD
Topotecan—Muscle spasms—Capecitabine—kidney cancer	3.32e-05	0.000485	CcSEcCtD
Topotecan—Hyperhidrosis—Paclitaxel—kidney cancer	3.32e-05	0.000485	CcSEcCtD
Topotecan—Diarrhoea—Dactinomycin—kidney cancer	3.31e-05	0.000484	CcSEcCtD
Topotecan—Anorexia—Paclitaxel—kidney cancer	3.27e-05	0.000478	CcSEcCtD
Topotecan—Alanine aminotransferase increased—Doxorubicin—kidney cancer	3.26e-05	0.000476	CcSEcCtD
Topotecan—Vomiting—Sunitinib—kidney cancer	3.25e-05	0.000475	CcSEcCtD
Topotecan—Body temperature increased—Gemcitabine—kidney cancer	3.24e-05	0.000474	CcSEcCtD
Topotecan—Rash—Sunitinib—kidney cancer	3.22e-05	0.000471	CcSEcCtD
Topotecan—Dermatitis—Sunitinib—kidney cancer	3.22e-05	0.000471	CcSEcCtD
Topotecan—Ill-defined disorder—Capecitabine—kidney cancer	3.2e-05	0.000468	CcSEcCtD
Topotecan—Headache—Sunitinib—kidney cancer	3.2e-05	0.000468	CcSEcCtD
Topotecan—Anaemia—Capecitabine—kidney cancer	3.19e-05	0.000466	CcSEcCtD
Topotecan—Hypersensitivity—Vincristine—kidney cancer	3.18e-05	0.000465	CcSEcCtD
Topotecan—Nausea—Sorafenib—kidney cancer	3.15e-05	0.000461	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Paclitaxel—kidney cancer	3.13e-05	0.000457	CcSEcCtD
Topotecan—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—kidney cancer	3.11e-05	0.00216	CbGpPWpGaD
Topotecan—Malaise—Capecitabine—kidney cancer	3.11e-05	0.000455	CcSEcCtD
Topotecan—Asthenia—Vincristine—kidney cancer	3.1e-05	0.000453	CcSEcCtD
Topotecan—Leukopenia—Capecitabine—kidney cancer	3.09e-05	0.000452	CcSEcCtD
Topotecan—Paraesthesia—Paclitaxel—kidney cancer	3.08e-05	0.000451	CcSEcCtD
Topotecan—Vomiting—Dactinomycin—kidney cancer	3.08e-05	0.00045	CcSEcCtD
Topotecan—Dyspnoea—Paclitaxel—kidney cancer	3.06e-05	0.000447	CcSEcCtD
Topotecan—Rash—Dactinomycin—kidney cancer	3.05e-05	0.000446	CcSEcCtD
Topotecan—Nausea—Sunitinib—kidney cancer	3.03e-05	0.000444	CcSEcCtD
Topotecan—Pancytopenia—Doxorubicin—kidney cancer	3.03e-05	0.000443	CcSEcCtD
Topotecan—Dyspepsia—Paclitaxel—kidney cancer	3.02e-05	0.000442	CcSEcCtD
Topotecan—Cough—Capecitabine—kidney cancer	3.01e-05	0.00044	CcSEcCtD
Topotecan—Neutropenia—Doxorubicin—kidney cancer	2.99e-05	0.000436	CcSEcCtD
Topotecan—Decreased appetite—Paclitaxel—kidney cancer	2.98e-05	0.000436	CcSEcCtD
Topotecan—ABCG2—Fluoropyrimidine Activity—TP53—kidney cancer	2.97e-05	0.00206	CbGpPWpGaD
Topotecan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—kidney cancer	2.97e-05	0.00206	CbGpPWpGaD
Topotecan—Gastrointestinal disorder—Paclitaxel—kidney cancer	2.96e-05	0.000433	CcSEcCtD
Topotecan—Fatigue—Paclitaxel—kidney cancer	2.96e-05	0.000433	CcSEcCtD
Topotecan—Diarrhoea—Vincristine—kidney cancer	2.96e-05	0.000432	CcSEcCtD
Topotecan—Asthenia—Gemcitabine—kidney cancer	2.94e-05	0.00043	CcSEcCtD
Topotecan—Myalgia—Capecitabine—kidney cancer	2.94e-05	0.00043	CcSEcCtD
Topotecan—Arthralgia—Capecitabine—kidney cancer	2.94e-05	0.00043	CcSEcCtD
Topotecan—Chest pain—Capecitabine—kidney cancer	2.94e-05	0.00043	CcSEcCtD
Topotecan—Constipation—Paclitaxel—kidney cancer	2.93e-05	0.000429	CcSEcCtD
Topotecan—Pain—Paclitaxel—kidney cancer	2.93e-05	0.000429	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	2.92e-05	0.000427	CcSEcCtD
Topotecan—Weight increased—Doxorubicin—kidney cancer	2.91e-05	0.000425	CcSEcCtD
Topotecan—Discomfort—Capecitabine—kidney cancer	2.9e-05	0.000424	CcSEcCtD
Topotecan—Pruritus—Gemcitabine—kidney cancer	2.9e-05	0.000424	CcSEcCtD
Topotecan—Nausea—Dactinomycin—kidney cancer	2.87e-05	0.00042	CcSEcCtD
Topotecan—Pneumonia—Doxorubicin—kidney cancer	2.86e-05	0.000419	CcSEcCtD
Topotecan—Dizziness—Vincristine—kidney cancer	2.86e-05	0.000418	CcSEcCtD
Topotecan—Infestation—Doxorubicin—kidney cancer	2.85e-05	0.000416	CcSEcCtD
Topotecan—Infestation NOS—Doxorubicin—kidney cancer	2.85e-05	0.000416	CcSEcCtD
Topotecan—Feeling abnormal—Paclitaxel—kidney cancer	2.83e-05	0.000413	CcSEcCtD
Topotecan—Gastrointestinal pain—Paclitaxel—kidney cancer	2.81e-05	0.00041	CcSEcCtD
Topotecan—Diarrhoea—Gemcitabine—kidney cancer	2.8e-05	0.00041	CcSEcCtD
Topotecan—Infection—Capecitabine—kidney cancer	2.8e-05	0.000409	CcSEcCtD
Topotecan—Neuropathy peripheral—Doxorubicin—kidney cancer	2.79e-05	0.000408	CcSEcCtD
Topotecan—Stomatitis—Doxorubicin—kidney cancer	2.77e-05	0.000406	CcSEcCtD
Topotecan—Nervous system disorder—Capecitabine—kidney cancer	2.76e-05	0.000404	CcSEcCtD
Topotecan—Thrombocytopenia—Capecitabine—kidney cancer	2.76e-05	0.000403	CcSEcCtD
Topotecan—Vomiting—Vincristine—kidney cancer	2.75e-05	0.000402	CcSEcCtD
Topotecan—Skin disorder—Capecitabine—kidney cancer	2.74e-05	0.0004	CcSEcCtD
Topotecan—Sweating—Doxorubicin—kidney cancer	2.73e-05	0.000399	CcSEcCtD
Topotecan—Urticaria—Paclitaxel—kidney cancer	2.73e-05	0.000399	CcSEcCtD
Topotecan—Rash—Vincristine—kidney cancer	2.72e-05	0.000398	CcSEcCtD
Topotecan—Hyperhidrosis—Capecitabine—kidney cancer	2.72e-05	0.000398	CcSEcCtD
Topotecan—Dermatitis—Vincristine—kidney cancer	2.72e-05	0.000398	CcSEcCtD
Topotecan—Abdominal pain—Paclitaxel—kidney cancer	2.71e-05	0.000397	CcSEcCtD
Topotecan—Body temperature increased—Paclitaxel—kidney cancer	2.71e-05	0.000397	CcSEcCtD
Topotecan—Headache—Vincristine—kidney cancer	2.71e-05	0.000396	CcSEcCtD
Topotecan—Hepatobiliary disease—Doxorubicin—kidney cancer	2.69e-05	0.000394	CcSEcCtD
Topotecan—Epistaxis—Doxorubicin—kidney cancer	2.68e-05	0.000393	CcSEcCtD
Topotecan—Anorexia—Capecitabine—kidney cancer	2.68e-05	0.000393	CcSEcCtD
Topotecan—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—kidney cancer	2.64e-05	0.00183	CbGpPWpGaD
Topotecan—Vomiting—Gemcitabine—kidney cancer	2.61e-05	0.000381	CcSEcCtD
Topotecan—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—kidney cancer	2.59e-05	0.0018	CbGpPWpGaD
Topotecan—Rash—Gemcitabine—kidney cancer	2.58e-05	0.000378	CcSEcCtD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—JUN—kidney cancer	2.58e-05	0.00179	CbGpPWpGaD
Topotecan—Dermatitis—Gemcitabine—kidney cancer	2.58e-05	0.000378	CcSEcCtD
Topotecan—Haemoglobin—Doxorubicin—kidney cancer	2.57e-05	0.000376	CcSEcCtD
Topotecan—Headache—Gemcitabine—kidney cancer	2.57e-05	0.000375	CcSEcCtD
Topotecan—Nausea—Vincristine—kidney cancer	2.57e-05	0.000375	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Capecitabine—kidney cancer	2.57e-05	0.000375	CcSEcCtD
Topotecan—Rhinitis—Doxorubicin—kidney cancer	2.56e-05	0.000375	CcSEcCtD
Topotecan—Haemorrhage—Doxorubicin—kidney cancer	2.56e-05	0.000374	CcSEcCtD
Topotecan—Hypoaesthesia—Doxorubicin—kidney cancer	2.54e-05	0.000372	CcSEcCtD
Topotecan—Pharyngitis—Doxorubicin—kidney cancer	2.54e-05	0.000371	CcSEcCtD
Topotecan—Paraesthesia—Capecitabine—kidney cancer	2.53e-05	0.00037	CcSEcCtD
Topotecan—Hypersensitivity—Paclitaxel—kidney cancer	2.53e-05	0.00037	CcSEcCtD
Topotecan—Dyspnoea—Capecitabine—kidney cancer	2.51e-05	0.000367	CcSEcCtD
Topotecan—Dyspepsia—Capecitabine—kidney cancer	2.48e-05	0.000362	CcSEcCtD
Topotecan—Asthenia—Paclitaxel—kidney cancer	2.46e-05	0.00036	CcSEcCtD
Topotecan—Decreased appetite—Capecitabine—kidney cancer	2.45e-05	0.000358	CcSEcCtD
Topotecan—Nausea—Gemcitabine—kidney cancer	2.43e-05	0.000356	CcSEcCtD
Topotecan—Gastrointestinal disorder—Capecitabine—kidney cancer	2.43e-05	0.000355	CcSEcCtD
Topotecan—Fatigue—Capecitabine—kidney cancer	2.43e-05	0.000355	CcSEcCtD
Topotecan—Pruritus—Paclitaxel—kidney cancer	2.43e-05	0.000355	CcSEcCtD
Topotecan—Pain—Capecitabine—kidney cancer	2.41e-05	0.000352	CcSEcCtD
Topotecan—Constipation—Capecitabine—kidney cancer	2.41e-05	0.000352	CcSEcCtD
Topotecan—Diarrhoea—Paclitaxel—kidney cancer	2.35e-05	0.000343	CcSEcCtD
Topotecan—Feeling abnormal—Capecitabine—kidney cancer	2.32e-05	0.000339	CcSEcCtD
Topotecan—Angiopathy—Doxorubicin—kidney cancer	2.32e-05	0.000339	CcSEcCtD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—HIF1A—kidney cancer	2.32e-05	0.00161	CbGpPWpGaD
Topotecan—Immune system disorder—Doxorubicin—kidney cancer	2.31e-05	0.000337	CcSEcCtD
Topotecan—Gastrointestinal pain—Capecitabine—kidney cancer	2.3e-05	0.000337	CcSEcCtD
Topotecan—Mediastinal disorder—Doxorubicin—kidney cancer	2.3e-05	0.000337	CcSEcCtD
Topotecan—Chills—Doxorubicin—kidney cancer	2.29e-05	0.000335	CcSEcCtD
Topotecan—Dizziness—Paclitaxel—kidney cancer	2.27e-05	0.000332	CcSEcCtD
Topotecan—Alopecia—Doxorubicin—kidney cancer	2.26e-05	0.00033	CcSEcCtD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—VEGFA—kidney cancer	2.26e-05	0.00157	CbGpPWpGaD
Topotecan—Urticaria—Capecitabine—kidney cancer	2.24e-05	0.000327	CcSEcCtD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—APAF1—kidney cancer	2.24e-05	0.00155	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—JUND—kidney cancer	2.24e-05	0.00155	CbGpPWpGaD
Topotecan—Body temperature increased—Capecitabine—kidney cancer	2.23e-05	0.000326	CcSEcCtD
Topotecan—Abdominal pain—Capecitabine—kidney cancer	2.23e-05	0.000326	CcSEcCtD
Topotecan—Malnutrition—Doxorubicin—kidney cancer	2.22e-05	0.000325	CcSEcCtD
Topotecan—ABCG2—Transmembrane transport of small molecules—ANXA2—kidney cancer	2.21e-05	0.00153	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—SLC5A3—kidney cancer	2.21e-05	0.00153	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—ATP7B—kidney cancer	2.21e-05	0.00153	CbGpPWpGaD
Topotecan—Vomiting—Paclitaxel—kidney cancer	2.18e-05	0.000319	CcSEcCtD
Topotecan—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	2.18e-05	0.00151	CbGpPWpGaD
Topotecan—Rash—Paclitaxel—kidney cancer	2.16e-05	0.000316	CcSEcCtD
Topotecan—Dermatitis—Paclitaxel—kidney cancer	2.16e-05	0.000316	CcSEcCtD
Topotecan—Back pain—Doxorubicin—kidney cancer	2.15e-05	0.000315	CcSEcCtD
Topotecan—Headache—Paclitaxel—kidney cancer	2.15e-05	0.000314	CcSEcCtD
Topotecan—CYP3A4—Tryptophan metabolism—CYP1A1—kidney cancer	2.14e-05	0.00149	CbGpPWpGaD
Topotecan—Muscle spasms—Doxorubicin—kidney cancer	2.14e-05	0.000313	CcSEcCtD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—kidney cancer	2.12e-05	0.00147	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—ALDH1A1—kidney cancer	2.1e-05	0.00146	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—RYR1—kidney cancer	2.08e-05	0.00144	CbGpPWpGaD
Topotecan—Hypersensitivity—Capecitabine—kidney cancer	2.08e-05	0.000303	CcSEcCtD
Topotecan—Ill-defined disorder—Doxorubicin—kidney cancer	2.06e-05	0.000302	CcSEcCtD
Topotecan—Anaemia—Doxorubicin—kidney cancer	2.06e-05	0.000301	CcSEcCtD
Topotecan—Nausea—Paclitaxel—kidney cancer	2.04e-05	0.000298	CcSEcCtD
Topotecan—Asthenia—Capecitabine—kidney cancer	2.02e-05	0.000295	CcSEcCtD
Topotecan—Malaise—Doxorubicin—kidney cancer	2.01e-05	0.000293	CcSEcCtD
Topotecan—Pruritus—Capecitabine—kidney cancer	1.99e-05	0.000291	CcSEcCtD
Topotecan—Leukopenia—Doxorubicin—kidney cancer	1.99e-05	0.000291	CcSEcCtD
Topotecan—ABCG2—Metabolism—ACY1—kidney cancer	1.97e-05	0.00137	CbGpPWpGaD
Topotecan—Cough—Doxorubicin—kidney cancer	1.94e-05	0.000284	CcSEcCtD
Topotecan—Diarrhoea—Capecitabine—kidney cancer	1.93e-05	0.000282	CcSEcCtD
Topotecan—Chest pain—Doxorubicin—kidney cancer	1.89e-05	0.000277	CcSEcCtD
Topotecan—Myalgia—Doxorubicin—kidney cancer	1.89e-05	0.000277	CcSEcCtD
Topotecan—Arthralgia—Doxorubicin—kidney cancer	1.89e-05	0.000277	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	1.88e-05	0.000275	CcSEcCtD
Topotecan—Discomfort—Doxorubicin—kidney cancer	1.87e-05	0.000274	CcSEcCtD
Topotecan—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—kidney cancer	1.86e-05	0.00129	CbGpPWpGaD
Topotecan—Dizziness—Capecitabine—kidney cancer	1.86e-05	0.000272	CcSEcCtD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—ACHE—kidney cancer	1.84e-05	0.00128	CbGpPWpGaD
Topotecan—Anaphylactic shock—Doxorubicin—kidney cancer	1.82e-05	0.000265	CcSEcCtD
Topotecan—Infection—Doxorubicin—kidney cancer	1.8e-05	0.000264	CcSEcCtD
Topotecan—Vomiting—Capecitabine—kidney cancer	1.79e-05	0.000262	CcSEcCtD
Topotecan—Nervous system disorder—Doxorubicin—kidney cancer	1.78e-05	0.00026	CcSEcCtD
Topotecan—Thrombocytopenia—Doxorubicin—kidney cancer	1.78e-05	0.00026	CcSEcCtD
Topotecan—Rash—Capecitabine—kidney cancer	1.78e-05	0.00026	CcSEcCtD
Topotecan—Dermatitis—Capecitabine—kidney cancer	1.77e-05	0.000259	CcSEcCtD
Topotecan—Headache—Capecitabine—kidney cancer	1.76e-05	0.000258	CcSEcCtD
Topotecan—Skin disorder—Doxorubicin—kidney cancer	1.76e-05	0.000258	CcSEcCtD
Topotecan—Hyperhidrosis—Doxorubicin—kidney cancer	1.76e-05	0.000257	CcSEcCtD
Topotecan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	1.73e-05	0.0012	CbGpPWpGaD
Topotecan—Anorexia—Doxorubicin—kidney cancer	1.73e-05	0.000253	CcSEcCtD
Topotecan—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	1.71e-05	0.00119	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—ANXA1—kidney cancer	1.69e-05	0.00118	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—PDHB—kidney cancer	1.68e-05	0.00116	CbGpPWpGaD
Topotecan—Nausea—Capecitabine—kidney cancer	1.67e-05	0.000245	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Doxorubicin—kidney cancer	1.65e-05	0.000242	CcSEcCtD
Topotecan—Paraesthesia—Doxorubicin—kidney cancer	1.63e-05	0.000238	CcSEcCtD
Topotecan—Dyspnoea—Doxorubicin—kidney cancer	1.62e-05	0.000237	CcSEcCtD
Topotecan—Dyspepsia—Doxorubicin—kidney cancer	1.6e-05	0.000234	CcSEcCtD
Topotecan—Decreased appetite—Doxorubicin—kidney cancer	1.58e-05	0.000231	CcSEcCtD
Topotecan—ABCG2—Metabolism—CCBL1—kidney cancer	1.58e-05	0.00109	CbGpPWpGaD
Topotecan—Gastrointestinal disorder—Doxorubicin—kidney cancer	1.57e-05	0.000229	CcSEcCtD
Topotecan—Fatigue—Doxorubicin—kidney cancer	1.57e-05	0.000229	CcSEcCtD
Topotecan—Constipation—Doxorubicin—kidney cancer	1.55e-05	0.000227	CcSEcCtD
Topotecan—Pain—Doxorubicin—kidney cancer	1.55e-05	0.000227	CcSEcCtD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—PAK1—kidney cancer	1.52e-05	0.00106	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—JUNB—kidney cancer	1.52e-05	0.00106	CbGpPWpGaD
Topotecan—Feeling abnormal—Doxorubicin—kidney cancer	1.5e-05	0.000219	CcSEcCtD
Topotecan—Gastrointestinal pain—Doxorubicin—kidney cancer	1.48e-05	0.000217	CcSEcCtD
Topotecan—Urticaria—Doxorubicin—kidney cancer	1.44e-05	0.000211	CcSEcCtD
Topotecan—Body temperature increased—Doxorubicin—kidney cancer	1.44e-05	0.00021	CcSEcCtD
Topotecan—Abdominal pain—Doxorubicin—kidney cancer	1.44e-05	0.00021	CcSEcCtD
Topotecan—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—kidney cancer	1.43e-05	0.000989	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—EGR1—kidney cancer	1.42e-05	0.000987	CbGpPWpGaD
Topotecan—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	1.4e-05	0.000975	CbGpPWpGaD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—JUN—kidney cancer	1.4e-05	0.000969	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—GLIPR1—kidney cancer	1.37e-05	0.000948	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—PPAT—kidney cancer	1.37e-05	0.000948	CbGpPWpGaD
Topotecan—Hypersensitivity—Doxorubicin—kidney cancer	1.34e-05	0.000196	CcSEcCtD
Topotecan—Asthenia—Doxorubicin—kidney cancer	1.3e-05	0.00019	CcSEcCtD
Topotecan—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	1.29e-05	0.000896	CbGpPWpGaD
Topotecan—Pruritus—Doxorubicin—kidney cancer	1.28e-05	0.000188	CcSEcCtD
Topotecan—ABCG2—Metabolism—APRT—kidney cancer	1.27e-05	0.000881	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—FH—kidney cancer	1.27e-05	0.000881	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—kidney cancer	1.25e-05	0.000867	CbGpPWpGaD
Topotecan—ABCB1—Allograft Rejection—IL2—kidney cancer	1.24e-05	0.000863	CbGpPWpGaD
Topotecan—Diarrhoea—Doxorubicin—kidney cancer	1.24e-05	0.000182	CcSEcCtD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—kidney cancer	1.24e-05	0.000859	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—GSTT1—kidney cancer	1.24e-05	0.000857	CbGpPWpGaD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—VEGFA—kidney cancer	1.22e-05	0.000847	CbGpPWpGaD
Topotecan—Dizziness—Doxorubicin—kidney cancer	1.2e-05	0.000176	CcSEcCtD
Topotecan—ABCB1—Transmembrane transport of small molecules—ATP7B—kidney cancer	1.19e-05	0.000829	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—SLC5A3—kidney cancer	1.19e-05	0.000829	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—ANXA2—kidney cancer	1.19e-05	0.000829	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—GPC3—kidney cancer	1.19e-05	0.000828	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—SLC5A5—kidney cancer	1.17e-05	0.000809	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—CA2—kidney cancer	1.16e-05	0.000806	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—PTGS1—kidney cancer	1.16e-05	0.000803	CbGpPWpGaD
Topotecan—Vomiting—Doxorubicin—kidney cancer	1.15e-05	0.000169	CcSEcCtD
Topotecan—Rash—Doxorubicin—kidney cancer	1.14e-05	0.000167	CcSEcCtD
Topotecan—Dermatitis—Doxorubicin—kidney cancer	1.14e-05	0.000167	CcSEcCtD
Topotecan—Headache—Doxorubicin—kidney cancer	1.14e-05	0.000166	CcSEcCtD
Topotecan—ABCG2—Metabolism—ALAD—kidney cancer	1.13e-05	0.000785	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—SLC2A1—kidney cancer	1.13e-05	0.000781	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—ST3GAL2—kidney cancer	1.1e-05	0.000766	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—ALDH1A1—kidney cancer	1.08e-05	0.000749	CbGpPWpGaD
Topotecan—Nausea—Doxorubicin—kidney cancer	1.08e-05	0.000158	CcSEcCtD
Topotecan—ABCB1—Metabolism—ACY1—kidney cancer	1.07e-05	0.000739	CbGpPWpGaD
Topotecan—ABCB1—Allograft Rejection—VEGFA—kidney cancer	1.06e-05	0.000733	CbGpPWpGaD
Topotecan—CYP3A4—Phase 1 - Functionalization of compounds—POMC—kidney cancer	1.05e-05	0.000727	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—SLC5A3—kidney cancer	1.04e-05	0.000718	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—PGK1—kidney cancer	1.04e-05	0.000718	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—LDHB—kidney cancer	1.02e-05	0.000704	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—PDHB—kidney cancer	9.06e-06	0.000628	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—ABCB1—kidney cancer	8.89e-06	0.000617	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—CA9—kidney cancer	8.8e-06	0.000611	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—APC—kidney cancer	8.72e-06	0.000605	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—GSTP1—kidney cancer	8.56e-06	0.000594	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—CCBL1—kidney cancer	8.52e-06	0.000591	CbGpPWpGaD
Topotecan—CYP3A4—Metapathway biotransformation—GSTP1—kidney cancer	8.45e-06	0.000586	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—GSTM1—kidney cancer	7.87e-06	0.000546	CbGpPWpGaD
Topotecan—CYP3A4—Metapathway biotransformation—GSTM1—kidney cancer	7.76e-06	0.000539	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—CRABP1—kidney cancer	7.48e-06	0.000519	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—CYP1A1—kidney cancer	7.46e-06	0.000518	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—GLIPR1—kidney cancer	7.38e-06	0.000512	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—PPAT—kidney cancer	7.38e-06	0.000512	CbGpPWpGaD
Topotecan—CYP3A4—Metapathway biotransformation—CYP1A1—kidney cancer	7.36e-06	0.000511	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—ITPR2—kidney cancer	6.96e-06	0.000483	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—APRT—kidney cancer	6.86e-06	0.000476	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—FH—kidney cancer	6.86e-06	0.000476	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—kidney cancer	6.85e-06	0.000475	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—kidney cancer	6.77e-06	0.00047	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—kidney cancer	6.62e-06	0.000459	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—ACY1—kidney cancer	6.56e-06	0.000455	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—GPC3—kidney cancer	6.45e-06	0.000448	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—GSTT1—kidney cancer	6.34e-06	0.00044	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—ACHE—kidney cancer	6.34e-06	0.00044	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—SLC5A5—kidney cancer	6.3e-06	0.000437	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—CA2—kidney cancer	6.28e-06	0.000436	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—kidney cancer	6.27e-06	0.000435	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—ALAD—kidney cancer	6.12e-06	0.000424	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—SLC2A1—kidney cancer	6.09e-06	0.000422	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—SCARB1—kidney cancer	6.01e-06	0.000417	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—kidney cancer	5.98e-06	0.000415	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—ST3GAL2—kidney cancer	5.97e-06	0.000414	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—kidney cancer	5.97e-06	0.000414	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—PTGS1—kidney cancer	5.94e-06	0.000412	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—kidney cancer	5.93e-06	0.000411	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—ALDH1A1—kidney cancer	5.84e-06	0.000405	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—PSMD7—kidney cancer	5.83e-06	0.000404	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—kidney cancer	5.78e-06	0.000401	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—PGK1—kidney cancer	5.6e-06	0.000388	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—SLC5A3—kidney cancer	5.6e-06	0.000388	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—PDHB—kidney cancer	5.58e-06	0.000387	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—POMC—kidney cancer	5.56e-06	0.000386	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—BCHE—kidney cancer	5.53e-06	0.000383	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—LDHB—kidney cancer	5.49e-06	0.000381	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—SLC5A5—kidney cancer	5.46e-06	0.000379	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—SLC2A1—kidney cancer	5.27e-06	0.000366	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—CCBL1—kidney cancer	5.25e-06	0.000364	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	5.22e-06	0.000362	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—RAF1—kidney cancer	5.03e-06	0.000349	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	4.94e-06	0.000342	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	4.8e-06	0.000333	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—CA9—kidney cancer	4.76e-06	0.00033	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	4.7e-06	0.000326	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—PPAT—kidney cancer	4.55e-06	0.000316	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—GLIPR1—kidney cancer	4.55e-06	0.000316	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	4.44e-06	0.000308	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—GSTP1—kidney cancer	4.4e-06	0.000305	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—APRT—kidney cancer	4.23e-06	0.000293	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—FH—kidney cancer	4.23e-06	0.000293	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—ABCB1—kidney cancer	4.16e-06	0.000289	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	4.07e-06	0.000283	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—CRABP1—kidney cancer	4.05e-06	0.000281	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—GSTM1—kidney cancer	4.04e-06	0.00028	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—GPC3—kidney cancer	3.98e-06	0.000276	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	3.94e-06	0.000273	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—CA2—kidney cancer	3.87e-06	0.000268	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—CYP1A1—kidney cancer	3.83e-06	0.000266	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—ALAD—kidney cancer	3.77e-06	0.000262	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—ITPR2—kidney cancer	3.76e-06	0.000261	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—ST3GAL2—kidney cancer	3.68e-06	0.000255	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—ALDH1A1—kidney cancer	3.6e-06	0.000249	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—SLC5A3—kidney cancer	3.45e-06	0.000239	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—PGK1—kidney cancer	3.45e-06	0.000239	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—ACHE—kidney cancer	3.43e-06	0.000238	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—GSTT1—kidney cancer	3.43e-06	0.000238	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—LDHB—kidney cancer	3.38e-06	0.000235	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—SCARB1—kidney cancer	3.25e-06	0.000225	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—PTGS1—kidney cancer	3.21e-06	0.000223	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—PSMD7—kidney cancer	3.15e-06	0.000219	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—BCHE—kidney cancer	2.99e-06	0.000207	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—SLC5A5—kidney cancer	2.95e-06	0.000205	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—CA9—kidney cancer	2.93e-06	0.000203	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—POMC—kidney cancer	2.86e-06	0.000198	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—SLC2A1—kidney cancer	2.85e-06	0.000198	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	2.72e-06	0.000189	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—CRABP1—kidney cancer	2.49e-06	0.000173	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—GSTP1—kidney cancer	2.38e-06	0.000165	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—ITPR2—kidney cancer	2.32e-06	0.000161	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—PTGS2—kidney cancer	2.28e-06	0.000158	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—GSTM1—kidney cancer	2.18e-06	0.000152	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—ACHE—kidney cancer	2.11e-06	0.000147	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—GSTT1—kidney cancer	2.11e-06	0.000147	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—CYP1A1—kidney cancer	2.07e-06	0.000144	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—SCARB1—kidney cancer	2e-06	0.000139	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—PTEN—kidney cancer	1.99e-06	0.000138	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—PTGS1—kidney cancer	1.98e-06	0.000137	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—PSMD7—kidney cancer	1.94e-06	0.000135	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—BCHE—kidney cancer	1.84e-06	0.000128	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—SLC5A5—kidney cancer	1.82e-06	0.000126	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—SLC2A1—kidney cancer	1.76e-06	0.000122	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—POMC—kidney cancer	1.54e-06	0.000107	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—GSTP1—kidney cancer	1.46e-06	0.000102	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—PIK3CA—kidney cancer	1.4e-06	9.72e-05	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—ABCB1—kidney cancer	1.39e-06	9.62e-05	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—GSTM1—kidney cancer	1.35e-06	9.34e-05	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—CYP1A1—kidney cancer	1.28e-06	8.85e-05	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—PTGS2—kidney cancer	1.23e-06	8.55e-05	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—PTEN—kidney cancer	1.07e-06	7.45e-05	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—POMC—kidney cancer	9.51e-07	6.6e-05	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—PTGS2—kidney cancer	7.59e-07	5.26e-05	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—PIK3CA—kidney cancer	7.58e-07	5.26e-05	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—PTEN—kidney cancer	6.62e-07	4.59e-05	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—PIK3CA—kidney cancer	4.67e-07	3.24e-05	CbGpPWpGaD
